Jefferies analyst Michael Sarcone maintained a Buy rating on Align Tech (ALGN – Research Report) yesterday and set a price target of $260.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Michael Sarcone has given his Buy rating due to a combination of factors including Align Tech’s commitment to innovation and geographic expansion. The company is focusing on new product developments and expanding its presence in underpenetrated markets, particularly in the EMEA region, which presents significant growth opportunities.
Additionally, Align Tech’s strategies to enhance orthodontic penetration through peer-to-peer programs and the upcoming launch of the next-generation ClinCheck with Invisalign personalized plans are expected to drive efficiency and productivity. These initiatives, along with improvements in manufacturing processes and increased adoption of iTero technology, are anticipated to support sustained growth and make Align Tech a promising investment.
Sarcone covers the Healthcare sector, focusing on stocks such as Align Tech, EDAP TMS, and Glaukos. According to TipRanks, Sarcone has an average return of -2.4% and a 37.93% success rate on recommended stocks.
In another report released on May 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $275.00 price target.